Literature DB >> 14997271

A comparison of d, l-fenfluramine and citalopram challenges in healthy adults.

Janine D Flory1, Stephen B Manuck, James M Perel, Matthew F Muldoon.   

Abstract

Dimensional personality characteristics (e.g. impulsivity) and related behaviors and psychiatric disorders are linked to abnormalities of central nervous system (CNS) serotonergic functioning. Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Citalopram, which inhibits serotonin reuptake, may serve as an alternative pre-synaptic neuropharmacologic challenge agent, due to its high selectivity and absence of intrinsic activity at serotonin or other receptor families. Twenty-two healthy adults who had been administered a fenfluramine challenge before May 1996 completed a 5-h oral citalopram challenge 3-6 years later. PRL responsivity to citalopram correlated significantly with PRL response to fenfluramine for baseline-corrected maximal and area-under-the-curve (AUC) indices ( r's > or =0.49, P's< or =0.02). The magnitude of the correlations is notable given the length of time between challenges. The results support the use of citalopram as an alternate neuroendocrine challenge to index CNS serotonergic responsivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997271     DOI: 10.1007/s00213-003-1763-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

2.  Low-dose citalopram as a 5-HT neuroendocrine probe.

Authors:  M J Attenburrow; P R Mitter; R Whale; T Terao; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2001-05       Impact factor: 4.530

3.  Citalopram.

Authors:  Andre F. Joubert; Connie Sánchez; Frank Larsen
Journal:  Hum Psychopharmacol       Date:  2000-08       Impact factor: 1.672

4.  Retest reliability of prolactin response to dl-fenfluramine challenge in adults.

Authors:  Janine D Flory; Stephen B Manuck; Matthew F Muldoon
Journal:  Neuropsychopharmacology       Date:  2002-02       Impact factor: 7.853

Review 5.  Pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C Hiemke; S Härtter
Journal:  Pharmacol Ther       Date:  2000-01       Impact factor: 12.310

6.  The effects of age, gender, and season on serotonergic function in healthy subjects.

Authors:  R N Golden; J H Gilmore; R D Ekstrom; B Knight; R G Ruegg; H L Miller; S W Carson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1996-11       Impact factor: 5.067

7.  State and trait abnormalities in serotonin function in major depression.

Authors:  Zubin Bhagwagar; Richard Whale; Philip J Cowen
Journal:  Br J Psychiatry       Date:  2002-01       Impact factor: 9.319

8.  Effects of age and gender on CNS serotonergic responsivity in normal adults.

Authors:  P A McBride; H Tierney; M DeMeo; J S Chen; J J Mann
Journal:  Biol Psychiatry       Date:  1990-05-15       Impact factor: 13.382

9.  Prolactin response to fenfluramine and suicide attempt lethality in major depression.

Authors:  K M Malone; E M Corbitt; S Li; J J Mann
Journal:  Br J Psychiatry       Date:  1996-03       Impact factor: 9.319

10.  Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.

Authors:  J Henning; P Netter
Journal:  Int J Neuropsychopharmacol       Date:  2002-03       Impact factor: 5.176

View more
  9 in total

1.  Neurobiological Functioning and the Personality-Trait Hierarchy: Central Serotonergic Responsivity and the Stability Metatrait.

Authors:  Aidan G C Wright; Kasey G Creswell; Janine D Flory; Matthew F Muldoon; Stephen B Manuck
Journal:  Psychol Sci       Date:  2019-09-05

2.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

Review 3.  Neurobiological pathways linking socioeconomic position and health.

Authors:  Peter J Gianaros; Stephen B Manuck
Journal:  Psychosom Med       Date:  2010-05-24       Impact factor: 4.312

4.  Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.

Authors:  R Berardelli; E Margarito; F Ghiggia; A Picu; M Balbo; L Bonelli; R Giordano; I Karamouzis; M Bo; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2010-04-22       Impact factor: 4.256

5.  Metabolic and reproductive consequences of the serotonin transporter promoter polymorphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta).

Authors:  J B Hoffman; J R Kaplan; B Kinkead; S L Berga; M E Wilson
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

6.  Future suicide attempt and responses to serotonergic challenge.

Authors:  John G Keilp; Maria A Oquendo; Barbara H Stanley; Ainsley K Burke; Thomas B Cooper; Kevin M Malone; J John Mann
Journal:  Neuropsychopharmacology       Date:  2008-03-19       Impact factor: 7.853

Review 7.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 8.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Authors:  Jonathan Hamill; Jaime Hallak; Serdar M Dursun; Glen Baker
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

9.  Acute hormonal changes after IV citalopram and treatment response in OCD.

Authors:  Fábio M Corregiari; Wagner F Gattaz; Márcio Bernik
Journal:  Psychopharmacology (Berl)       Date:  2007-05-10       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.